Revising the high-density lipoprotein targeting strategies – Insights from human and preclinical studies

References

• , Cholesterol Treatment Trialists’ (CTT) CollaborationBaigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010;376:1670–81
   PubMed Web of Science ®Google Scholar
• Fruchart J-C, Davignon J, Hermans MP, et al. Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol 2014;13:1–17
   PubMed Web of Science ®Google Scholar
• Kones R. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vasc Health Risk Manag 2013;9:617–70
   PubMedGoogle Scholar
• Lim S, Park YM, Sakuma I, Koh KK. How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol. Int J Cardiol 2013;166:8–14
   PubMed Web of Science ®Google Scholar
• Larach DB, deGoma EM, Rader DJ. Targeting high density lipoproteins in the prevention of cardiovascular disease? Curr Cardiol Rep 2012;14:684–91
   PubMed Web of Science ®Google Scholar
• Ng DS. Diabetic dyslipidemia: from evolving pathophysiological insight to emerging therapeutic targets. Can J Diabetes 2013;37:319–26
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Brewer HB, Davidson WS, et al. Cholesterol efflux and atheroprotection advancing the concept of reverse cholesterol transport. Circulation 2012;125:1905–19
   PubMed Web of Science ®Google Scholar
• Heinecke JW. The HDL proteome: a marker-and perhaps mediator-of coronary artery disease. J Lipid Res 2008;50:S167–71
   Web of Science ®Google Scholar
• Kiss RS, McManus DC, Franklin V, et al. The lipidation by hepatocytes of human apolipoprotein A-I occurs by both ABCA1-dependent and -independent pathways. J Biol Chem 2003;278:10119–27
   PubMed Web of Science ®Google Scholar
• Gillard BK, Lin H-YA, Massey JB, Pownall HJ. Apolipoproteins A-I, A-II and E are independently distributed among intracellular and newly secreted HDL of human hepatoma cells. Biochim Biophys Acta 2009;1791:1125–32
   PubMed Web of Science ®Google Scholar
• Ji A, Wroblewski JM, Cai L, et al. Nascent HDL formation in hepatocytes and role of ABCA1, ABCG1, and SR-BI. J Lipid Res 2012;53:446–55
   PubMed Web of Science ®Google Scholar
• Nagata KO, Nakada C, Kasai RS, et al. ABCA1 dimer-monomer interconversion during HDL generation revealed by single-molecule imaging. Proc Natl Acad Sci USA 2013;110:5034–9
   PubMed Web of Science ®Google Scholar
• Jonas A. Lecithin cholesterol acyltransferase. Biochim Biophys Acta 2000;1529:245–56
   PubMed Web of Science ®Google Scholar
• Chen B, Ren X, Neville T, et al. Apolipoprotein AI tertiary structures determine stability and phospholipid-binding activity of discoidal high-density lipoprotein particles of different sizes. Protein Sci 2009;18:921–35
   PubMed Web of Science ®Google Scholar
• Miller M, Zhan M. Genetic determinants of low high-density lipoprotein cholesterol. Curr Opin Cardiol 2004;19:380–4
   PubMed Web of Science ®Google Scholar
• Wang X, Rader DJ. Molecular regulation of macrophage reverse cholesterol transport. Curr Opin Cardiol 2007;22:368–72
   PubMed Web of Science ®Google Scholar
• Jessup W, Gelissen IC, Gaus K, Kritharides L. Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages. Curr Opin Lipidol 2006;17:247–57
   PubMed Web of Science ®Google Scholar
• Aiello RJ, Brees D, Bourassa PA, et al. Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler Thromb Vasc Biol 2002;22:630–7
   PubMed Web of Science ®Google Scholar
• Van Eck M, Singaraja RR, Ye D, et al. Macrophage ATP-binding cassette transporter A1 overexpression inhibits atherosclerotic lesion progression in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 2006;26:929–34
   PubMed Web of Science ®Google Scholar
• Oram JF, Lawn RM. ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J Lipid Res 2001;42:1173–9
   PubMed Web of Science ®Google Scholar
• Schmitz G, Brüning T, Williamson E, Nowicka G. The role of HDL in reverse cholesterol transport and its disturbances in Tangier disease and HDL deficiency with xanthomas. Eur Heart J 1990;11:197–211
   PubMed Web of Science ®Google Scholar
• Francone OL, Gong EL, Ng DS, et al. Expression of human lecithin-cholesterol acyltransferase in transgenic mice. Effect of human apolipoprotein AI and human apolipoprotein all on plasma lipoprotein cholesterol metabolism. J Clin Invest 1995;96:1440–8
   PubMed Web of Science ®Google Scholar
• Ng DS, Francone OL, Forte TM, et al. Disruption of the murine lecithin: cholesterol acyltransferase gene causes impairment of adrenal lipid delivery and up-regulation of scavenger receptor class B type I. J Biol Chem 1997;272:15777–81
   PubMed Web of Science ®Google Scholar
• Rader DJ, Ikewaki K, Duverger N, et al. Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin: cholesterol acyltransferase deficiency and fish-eye disease. J Clin Invest 1994;93:321–30
   PubMed Web of Science ®Google Scholar
• Swenson TL. The role of the cholesteryl ester transfer protein in lipoprotein metabolism. Diabetes Metab Rev 1991;7:139–53
   PubMed Web of Science ®Google Scholar
• Rashid S, Watanabe T, Sakaue T, Lewis GF. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem 2003;36:421–9
   PubMed Web of Science ®Google Scholar
• Acton S, Rigotti A, Landschulz KT, et al. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996;271:518–20
   PubMed Web of Science ®Google Scholar
• Babitt J, Trigatti B, Rigotti A, et al. Murine SR-BI, a high density lipoprotein receptor that mediates selective lipid uptake, is N-glycosylated and fatty acylated and colocalizes with plasma membrane caveolae. J Biol Chem 1997;272:13242–9
   PubMed Web of Science ®Google Scholar
• Kozarsky KF, Donahee MH, Rigotti A, et al. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature 1997;387:414–17
   PubMed Web of Science ®Google Scholar
• Rigotti A, Trigatti BL, Penman M, et al. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci USA 1997;94:12610–15
   PubMed Web of Science ®Google Scholar
• Braun A, Trigatti BL, Post MJ, et al. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E–deficient mice. Circ Res 2002;90:270–6
   PubMed Web of Science ®Google Scholar
• Trigatti BL, Krieger M, Rigotti A. Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:1732–8
   PubMed Web of Science ®Google Scholar
• Vergeer M, Korporaal SJA, Franssen R, et al. Genetic variant of the scavenger receptor BI in humans. New Engl J Med 2011;364:136–45
   PubMed Web of Science ®Google Scholar
• Miller GC, Long CJ, Bojilova ED, et al. Role of N-linked glycosylation in the secretion and activity of endothelial lipase. J Lipid Res 2004;45:2080–7
   PubMed Web of Science ®Google Scholar
• Yasuda T, Ishida T, Rader DJ. Update on the role of endothelial lipase in high-density lipoprotein metabolism, reverse cholesterol transport, and atherosclerosis. Circ J 2010;74:2263–70
   PubMed Web of Science ®Google Scholar
• Annema W, Tietge UJ. Role of hepatic lipase and endothelial lipase in high-density lipoprotein-mediated reverse cholesterol transport. Curr Atheroscler Rep 2011;13:257–65
   PubMed Web of Science ®Google Scholar
• Choi S, Korstanje R. Proprotein convertases in high-density lipoprotein metabolism. Biomark Res 2013;18:1–27
   Google Scholar
• The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New Engl J Med 2011;365:2255–67
   PubMed Web of Science ®Google Scholar
• HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34:1279–91
   PubMed Web of Science ®Google Scholar
• Boden WE, Sidhu MS, Toth PP. The therapeutic role of niacin in dyslipidemia management. Cardiovasc Pharmacol Ther 2014;19:141–58
   PubMed Web of Science ®Google Scholar
• Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001;285:1585–91
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849–61
   PubMed Web of Science ®Google Scholar
• , ACCORD Study GroupGinsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. New Engl J Med 2010;362:1563–74
   PubMed Web of Science ®Google Scholar
• Rosenblit PD. Do persons with diabetes benefit from combination statin and fibrate therapy? Curr Cardiol Rep 2012;14:112–24
   PubMed Web of Science ®Google Scholar
• McKeage K, Keating GM. Fenofibrate: a review of its use in dyslipidaemia. Drugs 2011;71:1917–46
   PubMed Web of Science ®Google Scholar
• Tenenbaum A, Fisman EZ. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol 2012;11:125
   PubMed Web of Science ®Google Scholar
• Barter PJ, Rye KA, Beltangady MS, et al. Relationship between atorvastatin dose and the harm caused by torcetrapib. J Lipid Res 2012;53:2436–42
   PubMed Web of Science ®Google Scholar
• Gotto AM, Cannon CP, Li XS, et al. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol 2014;113:76–83
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Brewer HB, Kastelein JJP, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011;306:2099–109
   PubMed Web of Science ®Google Scholar
• Ryan RO. Nanobiotechnology applications of reconstituted high density lipoprotein. J Nanobiotechnology 2010;8:28
   PubMedGoogle Scholar
• Maugeais C, Annema W, Blum D, et al. rHDL administration increasereverse cholesterol transport in mice, but is not additive on top of ezetimibe or cholestyramine treatment. Atherosclerosis 2013;229:94–101
   PubMed Web of Science ®Google Scholar
• Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 1990;85:1234–41
   PubMed Web of Science ®Google Scholar
• Shaw JA, Bobik A, Murphy A, et al. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res 2008;103:1084–91
   PubMed Web of Science ®Google Scholar
• Pászty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 1994;94:899–903
   PubMed Web of Science ®Google Scholar
• Vucic E, Rosenson RS. Recombinant high-density lipoprotein formulations. Curr Atheroscler Rep 2010;13:81–7
   Web of Science ®Google Scholar
• Waksman R, Torguson R, Kent KM, et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol 2010;55:2727–35
   PubMed Web of Science ®Google Scholar
• Tardif J-C, Grégoire J, L'Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007;297:1675–82
   PubMed Web of Science ®Google Scholar
• Krause BR, Remaley AT. Reconstituted HDL for the acute treatment of acute coronary syndrome. Curr Opin Lipidol 2013;24:480–6
   PubMed Web of Science ®Google Scholar
• Murphy AJ, Funt S, Gorman D, et al. Pegylation of high-density lipoprotein decreases plasma clearance and enhances antiatherogenic activity. Circ Res 2013;113:e1–e9
   PubMed Web of Science ®Google Scholar
• Ma CI, Beckstead JA, Thompson A, et al. Tweaking the cholesterol efflux capacity of reconstituted HDL. Biochem Cell Biol 2012;90:636–45
   PubMed Web of Science ®Google Scholar
• Ng DS, Leiter LA, Vezina C, et al. Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia. J Clin Invest 1994;93:223–9
   PubMed Web of Science ®Google Scholar
• Rubin EM, Krauss RM, Spangler EA, et al. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 1991;353:265–7
   PubMed Web of Science ®Google Scholar
• Umemoto T, Han CY, Mitra P, et al. Apolipoprotein AI and high-density lipoprotein have anti-inflammatory effects on adipocytes via cholesterol transporters: ATP-binding cassette A-1, ATP-binding cassette G-1, and scavenger receptor B-1. Circ Res 2013;112:1345–54
   PubMed Web of Science ®Google Scholar
• McNeill E. RVX-208, a stimulator of apolipoprotein AI gene expression for the treatment of cardiovascular diseases. Curr Opin Investig Drugs 2010;11:357–64
   PubMedGoogle Scholar
• Picaud S, Wells C, Felletar I, et al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc Natl Acad Sci USA 2013;110:19754–9
   PubMed Web of Science ®Google Scholar
• Marcil M, Brooks-Wilson A, Clee SM, et al. Mutations in the ABC 1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet 1999;354:1341–6
   PubMed Web of Science ®Google Scholar
• Brooks-Wilson A, Marcil M, Clee SM, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 1999;22:336–45
   PubMed Web of Science ®Google Scholar
• Gao M, Liu D. Resveratrol suppresses T0901317-induced hepatic fat accumulation in mice. AAPS J 2013;15:744–52
   PubMed Web of Science ®Google Scholar
• Rayner KJ, Suarez Y, Davalos A, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010;328:1570–3
   PubMed Web of Science ®Google Scholar
• Najafi-Shoushtari SH, Kristo F, Li Y, et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010;328:1566–9
   PubMed Web of Science ®Google Scholar
• Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002;109:1125–31
   PubMed Web of Science ®Google Scholar
• Gerin I, Clerbaux LA, Haumont O, et al. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J Biol Chem 2010;285:33652–61
   PubMed Web of Science ®Google Scholar
• Horie T, Ono K, Horiguchi M, et al. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci USA 2010;107:17321–6
   PubMed Web of Science ®Google Scholar
• Dávalos A, Goedeke L, Smibert P, et al. miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci USA 2011;108:9232–7
   PubMed Web of Science ®Google Scholar
• Li T, Francl JM, Boehme S, Chiang JYL. Regulation of cholesterol and bile acid homeostasis by the cholesterol 7α-hydroxylase/steroid response element-binding protein 2/microRNA-33a axis in mice. Hepatology 2013;58:1111–21
   PubMed Web of Science ®Google Scholar
• Rotllan N, Ramírez CM, Aryal B, et al. Therapeutic silencing of microRNA-33 inhibits the progression of atherosclerosis. Arterioscler Thromb Vasc Biol 2013; 33:1973–7
   PubMed Web of Science ®Google Scholar
• Marquart TJ, Wu J, Lusis AJ, Baldan A. Anti-miR-33 therapy does not alter the progression of atherosclerosis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2013;33:455–8
   PubMed Web of Science ®Google Scholar
• Rayner KJ, Sheedy FJ, Esau CC, et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 2011;121:2921–31
   PubMed Web of Science ®Google Scholar
• De Aguiar Vallim TQ, Tarling EJ, Kim T, et al. MicroRNA-144 regulates hepatic ATP binding cassette transporter A1 and plasma high-density lipoprotein after activation of the nuclear receptor farnesoid X receptor. Circ Res 2013;112:1602–12
   PubMed Web of Science ®Google Scholar
• Ramirez CM, Rotllan N, Vlassov AV, et al. Control of cholesterol metabolism and plasma high-density lipoprotein levels by microRNA-144. Circ Res 2013;112:1592–601
   PubMed Web of Science ®Google Scholar
• Ramirez CM, Davalos A, Goedeke L, et al. MicroRNA-758 regulates cholesterol efflux through posttranscriptional repression of ATP-binding cassette transporter A1. Arterioscler Thromb Vasc Biol 2011;31:2707–14
   PubMed Web of Science ®Google Scholar
• Toth PP, Barter PJ, Rosenson RS, et al. High-density lipoproteins: A consensus statement from the National Lipid Association. J Clin Lipidol 2013;7:484–525
   PubMed Web of Science ®Google Scholar
• Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered torecipient cells by high-density lipoproteins. Nat Cell Biol 2011;13:423–33
   PubMed Web of Science ®Google Scholar
• Kontush A, Lhomme M, Chapman MJ. Unraveling the complexities of the HDL lipidome. J Lipid Res 2013;54:2950–63
   PubMed Web of Science ®Google Scholar
• Huang Y, DiDonato JA, Levison BS, et al. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat Med 2014;20:193–203
   PubMed Web of Science ®Google Scholar
• DiDonato JA, Aulak K, Huang Y, et al. Site-specific nitration of apolipoprotein A-I at tyrosine 166 is both abundant within human atherosclerotic plaque and dysfunctional. J Biol Chem 2014;289:10276–92
   PubMed Web of Science ®Google Scholar
• Hewing B, Parathath S, Barrett T, et al. Effects of native and myeloperoxidase-modified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2014;34:779–89
   PubMed Web of Science ®Google Scholar
• Huang Y, Wu Z, Riwanto M, et al. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest 2013;123:3815–28
   PubMed Web of Science ®Google Scholar
• Riwanto M1, Rohrer L, Roschitzki B, et al. Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation 2013;127:891–904
   PubMed Web of Science ®Google Scholar
• Ng DS. The role of lecithin:cholesterol acyltransferase in the modulation of cardiometabolic risks - a clinical update and emerging insights from animal models. Biochim Biophys Acta 2012;1821:654–9
   PubMed Web of Science ®Google Scholar
• Calabresi L, Franceschini G. Lecithin:cholesterol acyltransferase, high-density lipoproteins, andatheroprotection in humans. Trends Cardiovasc Med 2010;20:50–3
   PubMed Web of Science ®Google Scholar
• Calabresi L, Baldassarre D, Castelnuovo S, et al. Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans. Circulation 2009;120:628–35
   PubMed Web of Science ®Google Scholar
• Duivenvoorden R, Holleboom AG, van den Bogaard B, et al. Carriers of lecithin cholesterol acyltransferase gene mutations have accelerated atherogenesis as assessed by Carotid 3.0-T magnetic resonance imaging. J Am Coll Cardiol 2011;58:2481–7
   PubMed Web of Science ®Google Scholar
• Chang PY, Lu SC, Su TC, et al. Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. J Lipid Res 2004;45:2116–22
   PubMed Web of Science ®Google Scholar
• Ng DS, Maguire GF, Wylie J, et al. Oxidative stress is markedly elevated in lecithin:cholesterol acyltransferase-deficient mice and is paradoxically reversed in the apolipoprotein E knockout background in association with a reduction in atherosclerosis. J Biol Chem 2002;277:11715–20
   PubMed Web of Science ®Google Scholar
• Lambert G, Sakai N, Vaisman BL, et al. Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferase-deficient mice. J Biol Chem 2001;276:15090–8
   PubMed Web of Science ®Google Scholar
• Furbee JW, Francone O, Parks JS. In vivo contribution of LCAT to apolipoprotein B lipoprotein cholesteryl esters in LDL receptor and apolipoprotein E knockout mice. J Lipid Res 2002;43:428–37
   PubMed Web of Science ®Google Scholar
• Ng DS, Xie C, Maguire GF, et al. Hypertriglyceridemia in lecithin-cholesterol acyltransferase-deficient mice is associated with hepatic overproduction of triglycerides, increased lipogenesis, and improved glucose tolerance. J Biol Chem 2004;279:7636–42
   PubMed Web of Science ®Google Scholar
• Li L, Hossain MA, Sadat S, et al. Lecithin cholesterol acyltransferase null mice are protected from diet-induced obesity and insulin resistance in a gender-specific manner through multiple pathways. J Biol Chem 2011;286:17809–20
   PubMed Web of Science ®Google Scholar
• Hager L, Li L, Pun H, et al. Lecithin:cholesterol acyltransferase deficiency protects against cholesterol-induced hepatic endoplasmic reticulum stress in mice. J Biol Chem 2012;287:20755–68
   PubMed Web of Science ®Google Scholar
• Song H, Zhu L, Picardo CM, et al. Coordinated alteration of hepatic gene expression in fatty acid and triglyceride synthesis in LCAT-null mice is associated with altered PUFA metabolism. Am J Physiol Endocrinol Metab 2006;290:E17–25
   Web of Science ®Google Scholar
• Xu N, Dahlback B. A novel human apolipoprotein (apoM). J Biol Chem 1999;274:31286–90
   PubMed Web of Science ®Google Scholar
• Christoffersen C, Nielsen LB, Axler O, et al. Isolation and characterization of human apolipoprotein M-containing lipoproteins. J Lipid Res 2006;47:1833–43
   PubMed Web of Science ®Google Scholar
• Christoffersen C, Nielsen LB. Apolipoprotein M: bridging HDL and endothelial function. Curr Opin Lipidol 2013;24:295–300
   PubMed Web of Science ®Google Scholar
• Ahnstrom, J, Axler O, Jauhiainen M, et al. Levels of apolipoprotein M are not associated with the risk of coronary heart disease in two independent case-control studies. J Lipid Res 2008;49:1912–17
   PubMed Web of Science ®Google Scholar
• Christoffersen C, Obinata H, Kumaraswamy SB, et al. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci USA 2011;108:9613–18
   PubMed Web of Science ®Google Scholar
• Liu M, Seo J, Allegood J, et al. Hepatic apolipoprotein M (apoM) overexpression stimulates formation of larger apoM/sphingosine 1-phosphate-enriched plasma high density lipoprotein. J Biol Chem 2014;289:2801–14
   PubMed Web of Science ®Google Scholar
• Burkart KM, Manichaikul A, Wilk JB, et al. APOM and high-density lipoprotein cholesterol are associated with lung function and per cent emphysema. Eur Respir J 2014;43:1003–17
   PubMed Web of Science ®Google Scholar
• Huang Y, Liu Y, Jiang L, et al. Apolipoprotein m (APOM) levels and APOM rs805297 G/T polymorphism are associated with increased risk of rheumatoid arthritis. Joint Bone Spine 2014;81:32–6
   PubMed Web of Science ®Google Scholar
• Hu Y, Chen Y, Ding L, et al. Pathogenic role of diabetes-induced PPAR-α down-regulation in microvascular dysfunction. Proc Natl Acad Sci USA 2013;110:15401–6
   PubMed Web of Science ®Google Scholar
• Chen Y, Hu Y, Lin M, et al. Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models. Diabetes 2013;62:261–72
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Ambrosius WT, Danis R, et al. Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial. Diabetes Care 2013;36:1266–71
   PubMed Web of Science ®Google Scholar